- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor INCB001158
- Arginase Inhibitor
CB-280 - CD73 Inhibitor
CB-708 - Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
November 2019
CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activityThe Society for Immunotherapy of Cancer
November 2019
Anti-tumor activity of a small molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)The Society for Immunotherapy of Cancer
September 2019
Phase 1 Study of the Arginase Inhibitor INCB001158 (1158) Alone and in Combination with Pembrolizumab in Patients with Advanced/Metastatic Solid TumorsEuropean Society for Medical Oncology
September 2019
ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat + everolimus vs. placebo + E in patients with advanced/metastatic renal cell carcinomaEuropean Society for Medical Oncology
April 2019
Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73American Association of Cancer Research
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.